Three sizable IPOs priced this past week, joined by a flurry of small issuers and blank check companies - Ingram Micro, ...

For a drugmaker advancing medicines through clinical trials, time is the enemy: the longer the process takes, the more costs ...

Yet, one analyst told Barron’s that “rarely in my 20 years as an analyst have I seen a company with so much potential.” He ...

Those around that level are, disproportionately, relatively small and risky companies whose prospects don't look all that ...

Investing in Cabaletta Bio for potential high returns on innovative CAR-T therapies despite volatility and risk. Click here ...

The crisis that has swept the biotech sector crashed into Medpace Holdings on Tuesday, sending shares of the drug-testing ...

Septerna CEO Jeffrey Finer rang the opening bell on the Nasd | South San Francisco-based Septerna has scored with an upsized ...

Discover top biotech associations that drive industry growth through collaboration, networking, and strategic partnerships ...

If Kevin and Stephanie Ness collect their $15 million asking price for the home on Sunset Blvd., it will be the second time ...

ISRO & Department of Biotechnology have come together to conduct a series of biotech experiments in space, some of which are ...

The key challenges in space missions are the continuous availability of nutrients, preservation of food, microgravity and radiation, health hazards such as cancers, cataracts, bone and muscle loss amo ...

Shortly after Bicara Therapeutics raised more than $360 million in an IPO, the cancer biotech and its former parent company ...